Revolution Medicines D
D
RVMD
172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
Revolution Medicines financials
Not at the moment. Revolution Medicines lost 1.87B USD over the last twelve months. It made a profit in 0 of its 9 fiscal years since 2017. Its last loss was in fiscal year 2025.
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- -1.87B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- -1.44B USD
- Cash and short-term investments
- 3.65B USD
- Total debt
- 639.10M USD
- Shareholders' equityWhat is a balance sheet? The balance sheet lists what a company owns (assets), what it owes (liabilities) and what is left for its shareholders (equity) on one date.
- 2.40B USD
Cash, debt and equity as of 30 Sept 2026.
Revolution Medicines earnings
Next earnings · Q4 FY2026
EPS estimate
-1.22 USD
Revenue estimate
388.66M USD
Last quarter · Q3 FY2026
EPS-1.90Beat +19.1%Revenue197.60MBeat +672.4%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2027 | -0.49 | — | — | — | 596.25M | — | — | +201.75% | |
| Q2 FY2027 | -0.66 | — | — | — | 522.96M | — | — | +29,392.47% | |
| Q1 FY2027 | -0.85 | — | — | — | 443.74M | — | — | +18,198.46% | |
| Q4 FY2026 | -1.22 | — | — | — | 388.66M | — | — | +10,467.83% | |
| Q3 FY2026 | -2.35 | -1.90 | +19.15% | — | 25.58M | 197.60M | +672.44% | +11,615.41% | |
| Q2 FY2026 | -2.04 | -3.06 | -50.00% | — | 1.77M | — | — | -93.56% | |
| Q1 FY2026 | -1.84 | -2.29 | -24.46% | — | 2.43M | — | — | +102.08% | |
| Q4 FY2025 | -1.58 | -1.86 | -17.72% | — | 3.68M | — | — | +880.74% | |
| Q3 FY2025 | -1.42 | -1.61 | -13.38% | — | 1.69M | — | — | +387.26% | |
| Q2 FY2025 | -1.14 | -1.31 | -15.11% | — | 27.53M | — | — | +3,308.48% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 0.66 | — | — | — | 3.36B | — | — | +68.13% |
| FY2027 | -2.95 | — | — | — | 2.00B | — | — | +251.90% |
| FY2026 | -8.51 | — | — | — | 568.29M | — | — | +16,210.40% |
| FY2025 | -5.65 | -5.91 | -4.65% | — | 3.48M | — | — | +1,061.40% |
| FY2024 | -3.47 | -3.57 | -2.80% | — | 300.00K | — | — | -97.63% |
| FY2023 | -3.48 | -3.77 | -8.41% | — | 12.65M | — | — | -64.24% |
| FY2022 | -3.29 | -3.10 | +5.83% | — | 27.86M | 35.38M | +26.98% | +20.38% |
Revolution Medicines growth and profitability
Full income statement- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 197.56M USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- -1.87B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 95.16%
- Operating margin
- -852.98%
- Net margin
- -946.82%
Revenue / Net income
Revenue Net income Net margin
Revolution Medicines revenue breakdown
By product
FY2022
100.0%Collaboration Revenue
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Collaboration Revenue | 35.38M | 100.0% | +20.4% |
Operating and free cash flow
Full cash flow statementOperating cash flow Free cash flow
Revolution Medicines financial health
Full balance sheet- Cash and short-term investments
- 3.65B USD
- Total debt
- 639.10M USD
- Net cash
- 3.01B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- -1.44B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 8.36
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.27
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 4 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 11.23
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Assets, liabilities and equity
Total assets Total liabilities Shareholders' equity
Revolution Medicines valuation
- Forward P/E (FY2028)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 259.13
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 188.62
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 15.52
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
37.26B USD
+
Total debt
639.10M USD
−
Cash and short-term investments
3.65B USD
=
Enterprise value
34.25B USD
Valuation over time
Revolution Medicines against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2019 to FY2023: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: United Therapeutics, Incyte, Insmed, Alnylam Pharmaceuticals, Exelixis, and Neurocrine Biosciences, the US Biotechnology companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- Gross marginAt its median100.0%100.0%100.0%Against its peers: 1 of 7Peers' median 90.3%
- Operating marginLowest in 5 years-4,207.1%-4,207.1%-108.2%Against its peers: 7 of 7Peers' median 23.9%
- Net marginLowest in 5 years-3,768.3%-3,768.3%-95.2%Against its peers: 7 of 7Peers' median 20.9%
- Return on equityAbove its median-23.9%-36.3%-22.8%Against its peers: 6 of 7Peers' median 21.9%
- Free cash flow marginLowest in 5 years-3,094.1%-3,094.1%-104.3%Against its peers: 7 of 7Peers' median 26.3%
- Revenue growthLowest in 5 years-67.3%-67.3%148.2%Against its peers: 7 of 7Peers' median 21.3%
- Current ratioHighest in 5 years13.063.1113.06Against its peers: 1 of 7Peers' median 3.48
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Revolution Medicines ownership
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 102.39%
- Institutional holders
- 738 (+179)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 90.07%
Who owns the shares
Institutions 100.0% Others 0.0%
As of 30 Jun 2026
Shares free to trade
Free float 194.80M shares ·90.1% Closely held 21.49M shares ·9.9%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 1 | 2.31K | 4.62K |
| Q3 2026 | 0 | 79 | 252.37K | 633.08K |
| Q2 2026 | 0 | 34 | 299.42K | 504.71K |
| Q1 2026 | 0 | 31 | 725.36K | 382.37K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Common questions about Revolution Medicines's financials
Source: Financial Modeling PrepVerified against SEC filings